3 resultados para Design de fármacos
em Universidade Federal do Rio Grande do Norte(UFRN)
Resumo:
A epilepsia é uma patologia crônica do sistema nervoso central que afeta cerca de 65 milhões de indivíduos no mundo. Aproximadamente 30% desses indivíduos desenvolvem crises convulsivas que persistem apesar do tratamento monitorado com drogas antiepiléptica s. Assim, há uma evidente necessidade do desenvolvimento de novos fármacos antiepilépticos e as peçonhas podem ser uma excelente fonte de modelos. Nesse contexto, enquanto já vários estudos sobre peçonhas de serpentes, escorpiões e aranhas, pouco se sabe s obre as peçonhas de formigas. Estudos prévios do nosso laboratório demonstraram que a peçonha desnaturada da formiga Dinoponera quadríceps protegeu camundongos de crises convulsivas e morte induzidas por bicuculina (BIC). Nesse contexto, o objetivo desse t rabalho foi investigar o potencial anticonvulsivante de frações isoladas da peçonha de D. quadríceps em crises convulsivas induzidas pela BIC, bem como uma análise dos efeitos dessas frações no comportamento natural dos camundongos no campo aberto. Os anim ais foram divididos em grupos, os quais receberam injeções (1 mg/ml i.c.v.) de seis frações distintas e tiveram seu comportamento geral observado no campo aberto durante 3 0 min. No segundo experimento, o s animais receberam as mesmas frações 20 min antes da administração de bicuculina (10 mg/ml). Em seguida, foi analisado o comportamento motor convulsivo desses animais durante 30 minutos no campo aberto. No primeiro experimento, não foram observadas alterações comportamentais. Já no segundo experimento, a ad ministração prévia de DqTx1, DqTx3, DqTx4 e DqTx6 aumentou a latência para o desenvolvimento de crises tônico - clônicas. Além disso, todas as frações, exceto DqTx5, aumentaram a latência para a morte dos animais. Ainda, os melhores resultados foram obtidos com a fração DqTx6, que protegeu 62,5% dos animais testados contra o desenvolvimento de crises tônico - clônicas e 100% dos animais contra a morte.
Resumo:
With the advances in medicine, life expectancy of the world population has grown considerably in recent decades. Studies have been performed in order to maintain the quality of life through the development of new drugs and new surgical procedures. Biomaterials is an example of the researches to improve quality of life, and its use goes from the reconstruction of tissues and organs affected by diseases or other types of failure, to use in drug delivery system able to prolong the drug in the body and increase its bioavailability. Biopolymers are a class of biomaterials widely targeted by researchers since they have ideal properties for biomedical applications, such as high biocompatibility and biodegradability. Poly (lactic acid) (PLA) is a biopolymer used as a biomaterial and its monomer, lactic acid, is eliminated by the Krebs Cycle (citric acid cycle). It is possible to synthesize PLA through various synthesis routes, however, the direct polycondensation is cheaper due the use of few steps of polymerization. In this work we used experimental design (DOE) to produce PLAs with different molecular weight from the direct polycondensation of lactic acid, with characteristics suitable for use in drug delivery system (DDS). Through the experimental design it was noted that the time of esterification, in the direct polycondensation, is the most important stage to obtain a higher molecular weight. The Fourier Transform Infrared (FTIR) spectrograms obtained were equivalent to the PLAs available in the literature. Results of Differential Scanning Calorimetry (DSC) showed that all PLAs produced are semicrystalline with glass transition temperatures (Tgs) ranging between 36 - 48 °C, and melting temperatures (Tm) ranging from 117 to 130 °C. The PLAs molecular weight characterized from Size Exclusion Chromatography (SEC), varied from 1000 to 11,000 g/mol. PLAs obtained showed a fibrous morphology characterized by Scanning Electron Microscopy (SEM)
Resumo:
With the advances in medicine, life expectancy of the world population has grown considerably in recent decades. Studies have been performed in order to maintain the quality of life through the development of new drugs and new surgical procedures. Biomaterials is an example of the researches to improve quality of life, and its use goes from the reconstruction of tissues and organs affected by diseases or other types of failure, to use in drug delivery system able to prolong the drug in the body and increase its bioavailability. Biopolymers are a class of biomaterials widely targeted by researchers since they have ideal properties for biomedical applications, such as high biocompatibility and biodegradability. Poly (lactic acid) (PLA) is a biopolymer used as a biomaterial and its monomer, lactic acid, is eliminated by the Krebs Cycle (citric acid cycle). It is possible to synthesize PLA through various synthesis routes, however, the direct polycondensation is cheaper due the use of few steps of polymerization. In this work we used experimental design (DOE) to produce PLAs with different molecular weight from the direct polycondensation of lactic acid, with characteristics suitable for use in drug delivery system (DDS). Through the experimental design it was noted that the time of esterification, in the direct polycondensation, is the most important stage to obtain a higher molecular weight. The Fourier Transform Infrared (FTIR) spectrograms obtained were equivalent to the PLAs available in the literature. Results of Differential Scanning Calorimetry (DSC) showed that all PLAs produced are semicrystalline with glass transition temperatures (Tgs) ranging between 36 - 48 °C, and melting temperatures (Tm) ranging from 117 to 130 °C. The PLAs molecular weight characterized from Size Exclusion Chromatography (SEC), varied from 1000 to 11,000 g/mol. PLAs obtained showed a fibrous morphology characterized by Scanning Electron Microscopy (SEM)